TY - JOUR
T1 - Soluble CD14
T2 - An independent biomarker for the risk of mother-to-child transmission of HIV in a setting of preexposure and postexposure antiretroviral prophylaxis
AU - Shivakoti, Rupak
AU - Gupta, Amita
AU - Ray, Jocelyn C.
AU - Uprety, Priyanka
AU - Gupte, Nikhil
AU - Bhosale, Ramesh
AU - Mave, Vidya
AU - Patil, Sandesh
AU - Balasubramanian, Usha
AU - Kinikar, Aarti
AU - Bharadwaj, Renu
AU - Bollinger, Robert C.
AU - Persaud, Deborah
N1 - Publisher Copyright:
© The Author 2015.
PY - 2015
Y1 - 2015
N2 - Elevated soluble CD14 (sCD14) concentrations, a marker of monocyte activation, predicts adverse outcomes in human immunodeficiency virus (HIV)-infected adults. To examine the association of sCD14 concentrations with the risk of motherto- child transmission (MTCT) of HIV, we nested a case-control study (49 pairs of infants and their HIV-infected mothers) within the Six-Week Extended-Dose Nevirapine trial. Median peripartum maternal log2 sCD14 concentration was higher among transmitters (defined as pairs in which maternally transmitted HIV infection occurred by 12 months of age) than nontransmitters (20.29 pg/mL vs 19.41 pg/mL; P = .005). There was an increased odds of MTCT for every log2 increase in maternal sCD14 concentration, after adjustment for maternal HIV load, CD4 count and cART exposure (adjusted odds ratio, 3.51; 95% confidence interval, 1.21-10.21). Maternal monocyte activation may adversely influence the risk of MTCT of HIV.
AB - Elevated soluble CD14 (sCD14) concentrations, a marker of monocyte activation, predicts adverse outcomes in human immunodeficiency virus (HIV)-infected adults. To examine the association of sCD14 concentrations with the risk of motherto- child transmission (MTCT) of HIV, we nested a case-control study (49 pairs of infants and their HIV-infected mothers) within the Six-Week Extended-Dose Nevirapine trial. Median peripartum maternal log2 sCD14 concentration was higher among transmitters (defined as pairs in which maternally transmitted HIV infection occurred by 12 months of age) than nontransmitters (20.29 pg/mL vs 19.41 pg/mL; P = .005). There was an increased odds of MTCT for every log2 increase in maternal sCD14 concentration, after adjustment for maternal HIV load, CD4 count and cART exposure (adjusted odds ratio, 3.51; 95% confidence interval, 1.21-10.21). Maternal monocyte activation may adversely influence the risk of MTCT of HIV.
KW - HIV
KW - Mother-to-child transmission
KW - sCD14
UR - http://www.scopus.com/inward/record.url?scp=84958658592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958658592&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiv479
DO - 10.1093/infdis/jiv479
M3 - Article
C2 - 26443598
AN - SCOPUS:84958658592
SN - 0022-1899
VL - 212
SP - 762
EP - 765
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 11
ER -